Pfizer Recalls More Quinapril Due to Potential Carcinogen
The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen.
Medscape Medical News
source https://www.medscape.com/viewarticle/972787?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/972787?src=rss
Comments
Post a Comment